

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
202.2D6APPLICATION NO.
10/741,929INFORMATION DISCLOSURE STATEMENT
BY APPLICANTAPPLICANT
Clarence N. Ahlem, et alFILING DATE
December 19, 2003GROUP
1617

(USE SEVERAL SHEETS IF NECESSARY)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	2,878,267	05/17/59	Szpilfogel et al			
	5,567,695	10/22/96	Labrie			
	5,763,433	06/09/98	Morfin			
	5,776,923	07/07/98	Labrie			
	<u>5,837,269</u>	11/17/98	Daynes et al.			
	6,077,873	06/20/00	Loozen			2/19/98

U.S. PATENT APPLICATION PUBLICATIONS

EXAMINER INITIAL	DOCUMENT PUBLICATION NUMBER	NAME AND PORTIONS OF DOCUMENT	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	US 2005/0075321 A1	Ahlem et al., first page and pages 102-107 (claims)			
	US 2004/0043973 A1	Ahlem et al., first page and pages 99-101 (claims)			
	US 2003/0119800 A1	Manolagas et al., entire document			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	EP 0 429 187 B1	05/01/94	Europe				
	<u>EP 0 289 327 A</u>	11/02/88	Europe				
	EP 01 133 995 A2	08/02/83	Europe				
	DE 38 12 595 C2	10/27/88	Germany			X	

EXAMINER

DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. 202.2D6	APPLICATION NO. 10/741,929
	APPLICANT Clarence N. Ahlem, et al	
	FILING DATE December 19, 2003	GROUP 1617

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
	Araghi-Niknam et al., Modulation of immune dysfunction during murine leukaemia retrovirus infection of old mice by dehydroepiandrosterone sulphate (DHEAS), <i>Immunology</i> 90:344-349 (1997)
	Araghi-Niknam et al., Cytokine Dysregulation and Increased Oxidation IS Prevented by Dehydroepiandrosterone in Mice Infected with Murine Leukemia Retrovirus, <i>Proc. Soc. Exp. Biol. Med.</i> 216(3):386-391 (1997)
	B. F. Bebo et al., Androgens alter the cytokine profile and reduce encephalitogenicity of myelin-reactive T cells, <i>J. Immunol.</i> 162:35-40 1999
	Henderson et al., Dehydroepiandrosterone and 16 α -bromoepiandrosterone: Inhibitors of Epstein-Barr virus induced transformation of human lymphocytes, <i>Carcinogenesis</i> , 2(7), pp. 683-686 1981
	Hernandez-Pando et al., The effects of androstenediol and dehydroepiandrosterone on the course and cytokine profile of tuberculosis in BALB/c mice, <i>Immunology</i> 95(2):234-241 1998
	P. Insera et al., Modulation of cytokine production by dehydroepiandrosterone (DHEA) plus melatonin (MLT) supplementation of old mice, <i>Proc. Soc. Exp. Biol. Med.</i> 218:76-82 1998
	Kang et al., Dehydroepiandrosterone and β -endorphin enhance IL-12 gene expression, <i>Taehan Misaengmulhak Hoechi (J. Korean Soc. Microbiology)</i> 31(4):399-404 (1996) (translation from Korean)
	Kang et al., Dehydroepiandrosterone and β -endorphin enhance IL-12 gene expression, <i>Chem Abstracts 2-Mammalian Hormones</i> 126(9) pp. 99 (Abstract 113406a)
	Kousteni S, et al. Reversal of bone loss in mice by nongenotropic signaling of sex steroids, <i>Science</i> 298:843-846 2002
	Manz et al., Methyl 17 β -Carboxyester Derivatives of Natural and Synthetic Glucocorticoids: Correlation Between Receptor Binding and Inhibition of in vitro Phytohaemagglutinin-Induced Lymphocyte Blastogenesis, <i>J. Clin. Chem. Clin. Biochem.</i> 21(2):69-75 (1983)
	Sigg et al., Methyl 3 α -acetoxyetien-(8:9 or 8:14)-ate, Preliminary Communication, <i>Helvetica Chimica Acta</i> , 39:1507-1525 1956 (translation from German)
	Xia P, et al. Anti-Aids agents. Part 36: 17-carboxylated steroids as potential anti-HIV agents, <i>BIOORG Med. Chem</i> 7(9), pp. 1907-1911 (Sep 1999)
	Yang et al., Inhibition of HIV-1 Latency Reactivation by Dehydroepiandrosterone (DHEA) and an Analog of DHEA, <i>Aids Research and Human Retroviruses</i> 9(8):747-754 (1993)
	Z. Zhang et al., Prevention of immune dysfunction and vitamin E loss by dehydroepiandrosterone and melatonin supplementation during murine retrovirus infection, <i>Immunology</i> 96:291-297 1999

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	